Somapacitan
FDA-approved weekly growth hormone (Sogroya).
What it's for
Somapacitan is recombinant human growth hormone with a fatty-acid linker enabling albumin binding and weekly dosing. Treats growth hormone deficiency in adults and pediatric patients as labeled.
What it does for the body
Treats growth hormone deficiency in adults and pediatric patients as labeled. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
growth hormone receptors (lock-and-key landing spots on cells) activation with extended how long it lasts in the body (how long it lasts in the body) versus daily somatropin. Imagine a thermostat for growth-hormone release: some peptides nudge the brain's release signals up, rather than pouring hormone in directly.
Research context
Bottom line for readers: Somapacitan has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Hormones research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Somapacitan — FDA.gov search
- ClinicalTrials.gov search: Somapacitan — U.S. clinical trials registry
- Drugs@FDA search: Somapacitan — FDA drug database (if approved)
- PubMed search: Somapacitan — NCBI PubMed
- PubMed Central search: Somapacitan — NCBI PMC